Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 11/20 | 0.56 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9654172 | 1.00 | BHMT (0.56) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL3444337 | 0.87 | BHMT (0.55) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL3444339 | 0.87 | BHMT (0.55) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL7363488 | 0.83 | ARG1 (0.42) | BHMTNOS2NOS3NOS1 | |
| SCHEMBL30983358 | 0.83 | ARG1 (0.42) | BHMTNOS2NOS3NOS1 | |
| SCHEMBL14597839 | 0.82 | GABRR1 (0.37) | BHMTBHMT2 | |
| SCHEMBL13062086 | 0.80 | HDAC3 (0.37) | BHMTNOS2NOS3NOS1 | |
| Benzene SCHEMBL27830440 | 0.79 | BHMT (0.57) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL172526 | 0.78 | SLC1A1 (0.52) | BHMT | |
| SCHEMBL1411236 | 0.78 | SLC1A1 (0.52) | BHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| WO-2025030117-A1 | FERROPTOSIS INDUCERS | ARPEGGIO BIOSCIENCES, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| EP-0998488-A1 | POLYOL-AMINO ACID COMPOUNDS HAVING ANTI-HELICOBACTER PYLORI ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2000-05-10 | — | — | EP | disclosed |
| EP-0975603-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999020612-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999002549-A1 | POLYOL-AMINO ACID COMPOUNDS HAVING ANTI-HELICOBACTER PYLORI ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-01-21 | — | — | WO | disclosed |
| CN-1039999-C | Vasopressin antagonist and oxytocin antagonist, process for their preparation and pharmaceutical compositions containing them | OTSUKA CHEMICAL CO LTD (JP) | 1998-09-30 | — | — | CN | disclosed |
| WO-1998032741-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 1998-07-30 | — | — | WO | disclosed |
| CN-1105984-A | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO CO (JP) | 1995-08-02 | — | — | CN | disclosed |
| EP-0427939-A2 | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1991-05-22 | — | — | EP | disclosed |
| US-4082736-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4082735-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | BHMT 2769/4885BHMT2 3482/4885NOS2 3301/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | BHMT 2712/4885BHMT2 2719/4885NOS2 1605/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | BHMT 2712/4885BHMT2 2719/4885NOS2 1605/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | BHMT 2890/4885BHMT2 3581/4885NOS2 3419/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | BHMT 2712/4885BHMT2 2719/4885NOS2 1605/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | BHMT 2712/4885BHMT2 2719/4885NOS2 1605/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | BHMT 2163/4885BHMT2 2060/4885NOS2 1360/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | BHMT 2712/4885BHMT2 2719/4885NOS2 1605/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | BHMT 2712/4885BHMT2 2719/4885NOS2 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.